Compare BFH & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFH | BEAM |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 2000 | 2019 |
| Metric | BFH | BEAM |
|---|---|---|
| Price | $85.52 | $31.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $80.64 | $50.75 |
| AVG Volume (30 Days) | 643.6K | ★ 2.0M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 98.36 | 82.31 |
| EPS | ★ 4.15 | N/A |
| Revenue | ★ $4,521,400,000.00 | $24,000.00 |
| Revenue This Year | $53.25 | N/A |
| Revenue Next Year | $3.53 | $33.77 |
| P/E Ratio | $20.53 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $47.87 | $15.52 |
| 52 Week High | $99.13 | $36.44 |
| Indicator | BFH | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 59.15 |
| Support Level | $68.65 | $22.24 |
| Resistance Level | $99.13 | $32.01 |
| Average True Range (ATR) | 3.27 | 1.81 |
| MACD | -0.60 | 0.01 |
| Stochastic Oscillator | 27.88 | 71.15 |
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.